Please login to the form below

Not currently logged in
Email:
Password:

Lilly to buy Alnara biotech

Eli Lilly has agreed to buy privately held biotech company Alnara which is focused on developing protein therapeutics for metabolic diseases

Eli Lilly and Company has signed a deal to buy the privately held biotech company Alnara, which is focused on developing protein therapeutics for metabolic diseases. The company also has one therapy already submitted for marketing approval with the US Food and Drug Administration (FDA).

The orally delivered product, called liprotamase, is a pancreatic enzyme replacement therapy under review for the treatment of exocrine pancreatic insufficiency (EPI), which can be caused by conditions such as cystic fibrosis, chronic pancreatitis and pancreatectomy. Patients with EPI can become malnourished due to an inability to properly digest and absorb fat, protein, and carbohydrates. About 90 per cent of cystic fibrosis patients receive pancreatic enzyme replacement, according to Lilly.

Liprotamase is designed to let patients take fewer pills than are needed with current therapies. It contains three active ingredients — lipase, protease, and amylase — that digest a broad spectrum of fats, proteins and carbohydrates, without the need for co-factors. The product is manufactured using a biotechnology source, unlike current porcine-based products, which involve harvesting pancreases from pigs.

Massachusetts-based Alnara licensed worldwide rights to liprotamase from Cystic Fibrosis Foundation Therapeutics, the non-profit affiliate of the Cystic Fibrosis Foundation, in early 2009. Liprotamase would be Lilly's first marketed product in the enzyme replacement therapy arena.

Alnara was launched in late 2008 and is headed up by Alexey Margolin, who is co-founder, president and CEO. Before founding Alnara, Margolin served as chief scientific officer and senior vice president of research and preclinical development at Altus Pharmaceuticals. Financial terms of the deal between Lilly and Alnara were not disclosed.

6th July 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

Robust Review: COVID19 Assessment
See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
Human behaviour - Sept 21
All change – how untangling human behaviour can encourage better health
Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...